Aseptic filling of dolasetron mesylate veterinary injectables operates within a narrow pH window because the mesylate salt converts to the poorly water-soluble free base above pH 4.5. In a 316L stainless steel jacketed dissolving vessel, the API is charged into Water for Injections at 20–25 °C and mixed at 150–300 rpm until a clear solution is obtained. The active concentration is expressed as dolasetron base equivalent. A 20.0 mg/mL solution therefore requires a salt-to-base correction calculated from the certificate of analysis assay value and the water content determined by USP <921>. The pH is adjusted to 3.2–4.0 with 0.1 N hydrochloric acid or a pre-dissolved citric acid monohydrate solution. Batch records define pH overshoot above 4.5 as a critical process deviation because filtration flux through a 0.22 µm PVDF membrane falls when precipitated free base particles exceed 0.45 µm in the prefiltration stream. A 0.45 µm polyethersulfone prefilter is installed before the final sterilizing-grade filter, and the membrane is integrity-tested by bubble point per ISO 2942 before and after filling. Filling is performed under Grade A laminar flow with a Grade B background into amber USP Type I borosilicate vials. Stopper insertion uses bromobutyl closures with fluoropolymer coating. Terminal steam sterilization at 121 °C for 15 min is generally replaced by aseptic filtration because published stability data for dolasetron in aqueous acidic solution indicates degradation under terminal autoclave conditions. Sterility is verified by USP <71>, visible particulate matter by USP <790>, and subvisible particulate matter by USP <788>. The terminal product is a clear, colourless to slightly yellow solution intended for intravenous administration, with an in-use hold time not exceeding 8 h at 20–25 °C after first stopper penetration.

What Limits Direct Compression Throughput for 50 mg Dolasetron Mesylate Tablets?

Direct compression of 50 mg dolasetron mesylate tablets is constrained by API particle size and the lubrication window. The API is pre-blended with an equal mass of lactose monohydrate 200 mesh through a 40 mesh stainless steel sieve to reduce agglomerates. The full blend contains 20.0 wt% dolasetron mesylate, 40.0 wt% microcrystalline cellulose PH102, 32.5 wt% lactose monohydrate 200 mesh, 4.0 wt% crospovidone, 2.0 wt% sodium citrate dihydrate, 0.5 wt% colloidal silicon dioxide, and 1.0 wt% magnesium stearate. Mixing is performed in a 500 L bin blender at 12 rpm for 20 min. Magnesium stearate is added in the final 3 min because prolonged lubrication above 5 min reduces tablet hardness and slows dissolution. Compression runs on a 27-station rotary press with 8 mm round concave tooling at a turret speed of 40–60 rpm. Precompression force is set at 5–8 kN, main compression at 18–24 kN, and tablet weight at 250 mg for a 50 mg dose expressed as dolasetron base equivalent. Hardness is maintained at 6–8 kp, friability at ≤1.0% after 100 revolutions per USP <1216>, and disintegration at ≤10 min in 0.1 N HCl per USP <701>. Content uniformity is assessed by USP <905> with an acceptance value ≤15.0. Dissolution uses USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 N HCl at 37 °C, with Q=80% at 30 min. The terminal tablet is packaged in Alu-Alu blister packs when the distribution climate exceeds 60% RH because moisture uptake can reduce blend flow and increase tablet hardness variability. Process limits include a final blend angle of repose ≤35° and a compressibility index ≤25% per USP <1174>.

Capsule Filling Grades and the D90 250 µm Cutoff

Automatic auger filling of hard gelatin capsules containing 25 mg dolasetron base equivalent requires a free-flowing powder with a D90 below 250 µm to prevent bridging in size 3 capsules. The capsule blend is pre-blended with lactose monohydrate 200 mesh and sodium citrate dihydrate. Typical composition is 12.5 wt% dolasetron mesylate, 83.5 wt% lactose monohydrate 200 mesh, 2.5 wt% sodium citrate dihydrate, 0.5 wt% colloidal silicon dioxide, and 1.0 wt% magnesium stearate. Pre-drying of lactose is required when loss on drying exceeds 2.0% per USP <731>. Blend flow is evaluated by EP 2.9.36 using a 10 mm orifice; a flow time of ≤25 s per 100 g is considered acceptable. The filling machine uses either an auger or dosator system with a fill weight of 200 mg and a target fill weight variation of ≤5.0%. Capsule body and cap are inspected after filling, and the finished capsule is dedusted on a rotating brush. Dissolution follows USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 N HCl at 37 °C, with a 30 min specification of ≥80% released. Packaging in PVC/PVDC/PE blister reduces moisture ingress and prevents shell deformation. Published data for this specific veterinary capsule configuration is limited. Process validation batches must therefore include dissolution profile comparison across 0.1 N HCl, pH 4.5 acetate buffer, and pH 6.8 phosphate buffer to establish a discriminating method.

Oral powders for extralabel veterinary administration are produced by geometric dilution when the dolasetron mesylate mass fraction is 10.0 mg/g as base. The API is first screened through a 300 µm stainless steel sieve and pre-blended with an equal portion of lactose monohydrate 200 mesh. The pre-blend is expanded with lactose monohydrate to a total batch size that occupies 60% of a 200 L ribbon blender. Sodium citrate dihydrate at 2.0 wt% is included as a pH modifier, and 0.5 wt% colloidal silicon dioxide is added to reduce electrostatic adhesion to the blender walls. Mixing proceeds at 40 rpm for 15 min. Ten thief samples are withdrawn and assayed. FDA 21 CFR 211.110 requires that routine manufacturing demonstrates adequacy of mixing, and an intermediate RSD ≤5.0% is used as an internal release criterion. The final powder is filled into three-ply paper/polyethylene/aluminium sachets at 20–25 °C and ≤35% RH. The terminal powder is intended for reconstitution with water or for mixing into a small quantity of food. Palatability remains a limiting factor because dolasetron mesylate is bitter and the addition of flavouring agents can alter dissolution behaviour. Storage below 25 °C in the moisture-impermeable sachet is required. The user should discard any remaining powder mixed with moist food after 2 h. No animal-specific pharmacokinetic data is available for all species; prescribing is therefore based on individual veterinary risk assessment and published small-animal references.

When a Drinking Water Premix Demands Acid Buffering Below pH 4.2

Wet granulation is selected for dolasetron mesylate drinking water premix because a granulated matrix reduces segregation and dust generation in high-humidity animal housing environments. The active is dry blended with dextrose monohydrate and anhydrous citric acid before granulation with purified water or an ethanol-water mixture of 95/5 v/v. Polyvinylpyrrolidone K30 at 3.0 wt% acts as a binder. The wet mass is passed through a 10 mesh sieve before tray drying at 45 °C. Drying is continued until loss on drying is ≤2.0% by USP <731>. The dried granulate is milled and classified to pass a 20 mesh sieve and retain on a 60 mesh sieve. Final premix concentration is 5.0 mg/g as dolasetron base. Anhydrous citric acid is included to maintain the reconstituted drinking water at pH 3.5–4.2, because above pH 4.5 the free base can precipitate and reduce dosing accuracy. The terminal premix is filled into HDPE drums with polyethylene liners and stored at ≤25 °C and ≤40% RH. Homogeneity is tested by sampling during drum filling. A UV or HPLC assay per USP <621> may be used after method verification. Stability studies follow VICH GL3 in climatic zone II at 25 °C/60% RH; published data for this specific granulated configuration is limited. Medicated drinking water is prepared fresh every 24 h. The stock solution should be protected from direct sunlight because photodegradation of dolasetron is not excluded by current stability datasets.

Oral liquid preparations containing dolasetron mesylate at 1.0–10.0 mg/mL as base are compounded as acidic solutions in 20 mM citrate buffer. The API is dissolved at 20–25 °C in purified water, then titrated with 1.0 N hydrochloric acid to pH 3.5–4.0. Sorbitol solution 70% is added if a viscosity increase is required to improve syringeability. Typical addition is 10–20 wt% of the final volume. Flavour masking is not straightforward because the mesylate salt contributes a strong bitter taste; veterinary oral solution formulations therefore rely on direct oral dosing rather than voluntary consumption. The solution is filtered through a 15 µm clarifying filter and filled into amber polyethylene terephthalate bottles with child-resistant closures. A preservative is required for multi-dose containers. Sodium benzoate 0.1 wt% or potassium sorbate 0.1 wt% may be used only after antimicrobial effectiveness testing per USP <51>. Terminal quality testing includes assay by HPLC per USP <621>, pH per USP <791>, and a 12-month semi-permeable container stability program in accordance with VICH GL1. The main operational boundary is that dissolved oxygen accelerates oxidation. Nitrogen sparging before bottle filling is therefore used when headspace oxygen exceeds 5.0% v/v. The finished product is intended for small-animal use under veterinary supervision. The bottle should be used within 28 days of first opening unless the preservative effectiveness test supports a longer in-use period.